title: Predictive assay of neoadjuvant chemotherapy in management of oral cancer.
abstract: Neoadjuvant chemotherapy (NAC) for oral squamous cell carcinoma has a positive impact on organ preservation and/or survival only in patients who achieve an excellent anti-tumour effect with this therapy. Predictive assay for NAC can play an important role in establishing tailor-made treatments for oral squamous cell carcinoma. In this retrospective study, the anti-tumour effects of cisplatin-based NAC in 70 patients with oral squamous cell carcinoma were reviewed in relation to biological markers of tumour cell proliferation activity: tumour grade, cellular DNA content, mitotic index, apoptotic index, ki-67 positive rate, and p53 and Bax expression. Tumour grade, Bax expression, apoptotic index and cellular DNA content were significantly correlated with the anti-tumour effects of NAC in univariate analysis. Tumour grade, Bax expression and apoptotic index were selected as independent predictive factors by means of multiple logistic analysis. Using the regression equation from these results, the prediction rate for anti-tumour effects was 70%. For patients in whom NAC is predicted to be ineffective, it may be necessary to choose another treatment option in order to improve their survival and quality of life.
authors.affiliation: Department of Oral Surgery, Sapporo Medical University, School of Medicine, South 1 West 16, Chuo-ku, Sapporo 060-8543, Japan. omfs@amber.plala.or.jp
authors.forename: T
authors.initials: T
authors.lastname: Tsuji
authors.forename: M
authors.initials: M
authors.lastname: Noguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kido
authors.forename: H
authors.initials: H
authors.lastname: Kubota
authors.forename: K
authors.initials: K
authors.lastname: Takemura
authors.forename: K
authors.initials: K
authors.lastname: Nakamori
authors.forename: H
authors.initials: H
authors.lastname: Hiratsuka
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008940:Mitotic Index; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis
chemical_list: C494826:BAX protein, human; D051028:bcl-2-Associated X Protein; D001761:Bleomycin; D002945:Cisplatin